Applied Genetic Technologies Quick Ratio (AGTC) starting from the first quarter 2022 to first quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Applied Genetic Technologies Corporation  (NASDAQ: AGTC)

Applied Genetic Technologies's Quick Ratio

AGTC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Applied Genetic Technologies's Cash & cash equivalent, this led to improvement in Applied Genetic Technologies's Quick Ratio to 1.29, Quick Ratio remained below Applied Genetic Technologies Corporation average.

Within Biotechnology & Pharmaceuticals industry 163 other companies have achieved higher Quick Ratio than Applied Genetic Technologies in first quarter 2022. While Quick Ratio total ranking in the first quarter 2022 has deteriorated compared to the prior quarter from 1812 to 2143.

Explain Quick Ratio?
How much Cash & cash equivalents AGTC´s has?
What are AGTC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AGTC Quick Ratio (Sep 30 2022)
Q1		 (Jun 30 2022)
Q4		 (Mar 31 2022)
Q3		 (Dec 31 2021)
Q2		 (Sep 30 2021)
Q1
Y / Y Current Liabilities Change 22.55 % 783.67 % 55.92 % 69.29 % 66.84 %
Y / Y Cash & cash equivalent Change -62.17 % -56.69 % -38.89 % 37.05 % 36 %
Quick Ratio MRQ 1.29 0.27 2.63 3.02 4.17
AGTC's Total Ranking # 2143 # 1812 # 1818 # 165 # 1068
Seq. Current Liabilities Change -84.73 % 574.99 % 7.03 % 11.08 % 10.12 %
Seq. Cash & cash equivalent Change -26.15 % -31.66 % -6.76 % -19.6 % -15.45 %



Quick Ratio first quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 164
Healthcare Sector # 855
Overall Market # 2143


Quick Ratio Statistics
High Average Low
28.84 7.47 1.29
(Jun 30 2014)   (Sep 30 2022)




Financial Statements
Applied Genetic Technologies's Current Liabilities $ 27 Millions Visit AGTC's Balance sheet
Applied Genetic Technologies's Cash & cash equivalent $ 34 Millions Visit AGTC's Balance sheet
Source of AGTC's Sales Visit AGTC's Sales by Geography


Cumulative Applied Genetic Technologies's Quick Ratio

AGTC's Quick Ratio for the trailling 12 Months

AGTC Quick Ratio

 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 247.18 % 287.01 % 56.46 % 48.24 % 28.81 %
Y / Y Cash & cash equivalent TTM Growth -38.84 % -17.83 % 8.69 % 33.99 % 22.99 %
Quick Ratio TTM 0.88 1.13 3.7 4.65 5.01
Total Ranking TTM # 4466 # 4397 # 1069 # 3864 # 4266
Seq. Current Liabilities TTM Growth 1.99 % 169.13 % 11.28 % 13.67 % 13.69 %
Seq. Cash & cash equivalent TTM Growth -20.28 % -17.94 % -11.32 % 5.44 % 7.09 %

Quick ratio ranking by company, industry and sector >> Back to AGTC Financial Strength Comparisons >> Go to Compare AGTC Quick Ratio to its Competitors

On the trailing twelve months basis Due to drop in Current Liabilities in the Q1 2022 to $26.60 millions, cumulative Quick Ratio decreased to 0.88 below the Applied Genetic Technologies Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 190 other companies have achieved higher Quick Ratio than Applied Genetic Technologies. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4397 to 4466.

Explain Quick Ratio?
How much Cash & cash equivalents AGTC´s has?
What are AGTC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 191
Healthcare Sector # 1162
Within the Market # 4466


trailing twelve months Quick Ratio Statistics
High Average Low
20.16 5.18 2.17
(June 30. 2015)   (Sep 30 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Fresh Tracks Therapeutics Inc   3.51 $ 11.250  Millions$ 3.206  Millions
Precision Biosciences Inc  3.47 $ 212.051  Millions$ 61.148  Millions
Genfit S a   3.45 $ 152.321  Millions$ 44.094  Millions
Erytech Pharma S a   3.32 $ 43.444  Millions$ 13.079  Millions
Immunocore Holdings Plc  3.27 $ 402.716  Millions$ 123.083  Millions
Regenxbio Inc   3.10 $ 382.418  Millions$ 123.548  Millions
Denali Therapeutics Inc   3.07 $ 1,106.055  Millions$ 360.670  Millions
Greenlight Biosciences Holdings Pbc  3.03 $ 98.353  Millions$ 32.416  Millions
Adaptimmune Therapeutics Plc  3.02 $ 199.670  Millions$ 66.080  Millions
Vaxart Inc   2.94 $ 63.999  Millions$ 21.740  Millions
Lineage Cell Therapeutics Inc   2.92 $ 66.355  Millions$ 22.739  Millions
Qiagen N v   2.90 $ 1,418.266  Millions$ 488.286  Millions
X4 Pharmaceuticals Inc  2.90 $ 79.855  Millions$ 27.549  Millions
Aptose Biosciences Inc   2.84 $ 28.293  Millions$ 9.963  Millions
Argenx Se  2.65 $ 800.740  Millions$ 302.277  Millions
Sangamo Therapeutics Inc   2.56 $ 313.568  Millions$ 122.361  Millions
Seagen Inc   2.43 $ 1,763.702  Millions$ 725.998  Millions
Orchard Therapeutics Plc  2.43 $ 146.554  Millions$ 60.339  Millions
Halozyme Therapeutics Inc   2.43 $ 265.584  Millions$ 109.384  Millions
Windtree Therapeutics Inc  2.39 $ 8.436  Millions$ 3.535  Millions
Oyster Point Pharma Inc   2.36 $ 68.800  Millions$ 29.197  Millions
Nanostring Technologies Inc   2.30 $ 117.069  Millions$ 50.939  Millions
Cellectis S a   2.17 $ 104.653  Millions$ 48.131  Millions
Innate Pharma Sa  2.04 $ 94.332  Millions$ 46.299  Millions
Old Ayala Inc   1.96 $ 11.195  Millions$ 5.705  Millions
Redwoods Acquisition Corp  1.90 $ 0.414  Millions$ 0.218  Millions
Freeline Therapeutics Holdings Plc  1.89 $ 65.848  Millions$ 34.857  Millions
Biocardia Inc   1.81 $ 6.667  Millions$ 3.684  Millions
Evaxion A  1.78 $ 13.973  Millions$ 7.864  Millions
Pluri Inc   1.74 $ 8.744  Millions$ 5.018  Millions

Date modified: 2026-09-08T15:10:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.